1. Introduction {#sec1-ijerph-16-03890}
===============

Despite attempts by professional societies to standardize acute myocardial infarction (AMI) care through the guidelines, substantial variation exists in the practice patterns for the management of AMI in hospitals around the world. In the era of accountability in the therapeutic field, evaluation of quality of care plays a vital role and has turned into an imperative tool for health specialists and experts \[[@B1-ijerph-16-03890]\]. However, assessing the quality of care in patients admitted for acute myocardial infarction (AMI) is challenging because it is a complex notion that is based on a wide broad variety of factors not restricted to positive clinical results only \[[@B2-ijerph-16-03890]\]. Therefore, evaluation of the quality of care by quality indicators (QIs) has become a standard, global practice that captures the detailed outcome of treatment programs accurately \[[@B3-ijerph-16-03890],[@B4-ijerph-16-03890],[@B5-ijerph-16-03890],[@B6-ijerph-16-03890]\]. Several countries and territories have introduced a number of QIs to evaluate and assess the quality of health care in AMI patients \[[@B7-ijerph-16-03890],[@B8-ijerph-16-03890],[@B9-ijerph-16-03890],[@B10-ijerph-16-03890],[@B11-ijerph-16-03890],[@B12-ijerph-16-03890]\]. In a few western countries, the implementation of QIs for AMI patients has delivered significant outcomes and has likewise shown their capacity to identify fluctuations in care across hospitals \[[@B2-ijerph-16-03890],[@B3-ijerph-16-03890],[@B6-ijerph-16-03890],[@B13-ijerph-16-03890]\].

AMI is among the leading causes of death and disability worldwide. It has a strong significance in accomplishing rapid revascularization due to on-time diagnosis and treatment which largely affects survival \[[@B14-ijerph-16-03890]\]. Accurate burden assessment of patients with AMI in low- and middle-income countries is mostly unavailable; however, crude estimates indicate that the burden of AMI has been steadily increasing over the last decades in low- and middle-income countries \[[@B15-ijerph-16-03890]\]. Cardiovascular risk factors for ischemic heart disease and AMI are on the rise in Pakistan and a leading cause of morbidity and mortality \[[@B16-ijerph-16-03890]\]. However, Pakistan is spending less than 1% of the gross domestic product (GDP) on public health for the past few decades, while the World Health Organization (WHO) benchmark of health expenditure is at least 6% of the GDP \[[@B17-ijerph-16-03890]\].

Although individual QIs are useful to measure the outcomes for improvement activities, questions remain concerning how to use the available data to assess and quantify progress made in quality improvement. Composite measures aggregate individual QIs into a summary of performance across multiple dimensions of care, which allows an overall representation of healthcare quality provided and provides a more understandable format. To date, there has been no investigation done in context of Pakistan for assessing the quality of AMI care based upon the recommended guidelines or the association between the QIs and in-hospital outcomes. Previous studies \[[@B18-ijerph-16-03890]\] have emphasized the association between process of care measures and in-hospital outcome, but have been limited ascertainment of in-hospital events, which can be substantially biased by in-hospital length of stay. Thus, the degree to which process measure performance conveys meaningful information about in-hospital mortality remains unclear. To address the above-mentioned needs, we aimed to estimate the compliance rate of QIs, and examine the association between quality indicators care and in-hospital outcomes among ST Segment Elevation Myocardial Infarction (STEMI) and Non-ST Segment Elevation Myocardial Infarction (NSTEMI) patients, including individual QIs and patient composite score. Identifying valid QIs for AMI treatment and their impact on in-hospital outcomes, is an important tool for improving the quality of health care.

To the best of our insight, this study is the first of its kind done in the Pakistani population to assess the relationship between quality care and in-hospital outcomes among AMI patients. The primary quality of our investigation is that it provides the most recent statistics for evaluating quality of care delivery for patients with AMI in Pakistan. Also, it provides an estimation of composite score from the patient dimension using quality indicators.

2. Methods {#sec2-ijerph-16-03890}
==========

2.1. Data Source and Study Population {#sec2dot1-ijerph-16-03890}
-------------------------------------

A retrospective study plan has been carried out in 11 Coronary Care Units (CCU), in tertiary of Punjab, Pakistan. Information was derived from administrative hospital discharge data of AMI patients from 1 January 2016 to 31 December 2017 by three trained bio-statisticians. This study chooses the big cities of Punjab, such as Faisalabad, Lahore, Multan, Rawalpindi, and Islamabad, to measure the quality of care and its impact on in-hospital outcomes among AMI patients who have a strong economic background. The details of geographical, racial and economic factors of Punjab cities are available at the Pakistan Bureau of Statistics \[[@B19-ijerph-16-03890]\]. The study population consisted of patients who presented to emergency room within 24 h of the onset of an ischemic syndrome, and the ultimate primary diagnosis was AMI labeled as either STEMI or NSTEMI. Variables include patient demographics, clinical presentation, medical history, cardiovascular risk factors, co-morbidities, timings of care conveyance; treatments advised as well as major contraindications related to treatments, post-hospital discharge therapy, and in-hospital patient outcomes.

For hospitals with more prominent than 300 AMI cases, we excluded those that had no patient's outcome(death/survival). Thus, we were left with only 300 cases. For hospitals fewer than 300 AMI cases, all were chosen. Patients were excluded in the final analysis on the off chance that they were hospitalized for more than 90 days, in the event that they were transferred from another acute care facility, in the case they had stayed \< 1 day and discharged alive, and those with had lost information. After avoidance, a total of 2663 AMI cases---1454 STEMI and 1209 NSTEMI, were cleared out for final investigations. Ethical approval for the study was obtained from Ethics Review Committee of all hospital regulatory body Ministry of health Pakistan approval reference (KIIT 2019/PK 2019-25- MS 65).

2.2. Quality Indicators {#sec2dot2-ijerph-16-03890}
-----------------------

Quality of care for AMI patients was investigated using 13 QIs at the primary and secondary levels. The relationship between adherence to these indicators and in-hospital outcomes was evaluated. The indicators of quality care measures included were the in-hospital advise of aspirin (QI1), beta blockers (QI2), clopidogrel (QI3), thrombolytic (QI4), electrocardiograph (ECG) (QI5), left ventricular function(LVF) assessment (QI6), coronary angiography (QI7), primary percutaneous coronary intervention(PCI) (QI8) and at secondary level, use of aspirin (QI9), beta-blocker (QI10), Angiotensin-Converting Enzyme (ACE) Inhibitor (QI11), Statin (QI12), Clopidogrel (QI13) at post-discharge. These measures are proposed by the Chinese health care system based upon the Modified Delphi process \[[@B20-ijerph-16-03890]\]. Unlike the indicators proposed by the American College of Cardiology and the American Heart Association (ACC/AHA), which consisted of only quality of care measures \[[@B21-ijerph-16-03890]\], The present investigation included additional structural and outcome indicators, based on the theoretical structure of Donabedian medical quality system \[[@B20-ijerph-16-03890],[@B21-ijerph-16-03890],[@B22-ijerph-16-03890],[@B23-ijerph-16-03890]\]. Due to many differences between Pakistan and other developed countries when comparing health-care systems and how diseases are treated, we focused on using Chinese quality indicators for AMI care as both are developing countries. In-hospital mortality and length of stay (LOS) were considered as outcome measures.

2.3. Statistical Analysis {#sec2dot3-ijerph-16-03890}
-------------------------

Baseline demographic characteristics of patients and co-morbidities for the selected population were summed up in the form of frequencies and percentages ([Table 1](#ijerph-16-03890-t001){ref-type="table"} and [Table 2](#ijerph-16-03890-t002){ref-type="table"}). In addition, for each baseline group, in-hospital mortality rate and LOS were also calculated as the outcome might also be influenced by patient's characteristics. We conducted a univariate analysis to examine the effects of patient characteristics and comorbidities on patient outcomes. Each QI was an independent variable separately and in-hospital outcome (mortality/LOS) was the dependent variable. The adherence rate was calculated for each QI as the sum of patients receiving care (numerator) divided by the number of patients meeting eligibility criteria (denominator) \[[@B20-ijerph-16-03890]\]. We calculated the patient composite score using the sum of numerator divided by the sum of denominator of all QIs. With patient-level and hospital-level risk factors as fixed effects and a random intercept for hospitals, unadjusted and adjusted hierarchical generalized linear model (HGLM) were used to investigate the impact of receiving treatment (usage of a single indicator/patient quality of care composite score) on in-hospital outcomes. For each QI, patients meeting the eligibility criteria were included in the analysis. The composite score was added as a continuous predictor variable, and regression coefficients were reported per 10% increment in composite score. All significant (*p* \< 0.05) risks factors (listed in [Table 1](#ijerph-16-03890-t001){ref-type="table"} and [Table 2](#ijerph-16-03890-t002){ref-type="table"}) in univariate analysis for patient characteristics were co-variables in the HGLM. Analysis of the abstracted data was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-ijerph-16-03890}
==========

3.1. Clinical Characteristics {#sec3dot1-ijerph-16-03890}
-----------------------------

[Table 1](#ijerph-16-03890-t001){ref-type="table"} indicates the baseline and clinical attributes of admissions for AMI. Among 2663 patients, 1859 (69.81%) of the admissions were male patients. In-hospital mortality rate accounted approximately same for both males and females as 8.55% and 8.58%, respectively. An aggregate of 1197 patients was \> 70 years old with a higher death rate of 9.11%. 2314 patients were reported as obese, with a mortality rate of 8.69%. Only 38% had health insurance. 56.37% were smokers and demonstrated a slightly higher rate of in-hospital mortality, i.e. 8.86% than those without smoking, i.e. 8.18%. Approximately, half of them had a family history of ischemic heart disease (42.32%). Among 2663 patients, 1052 had a background marked by hypertension and 909 had a history of diabetes mellitus. A number of STEMI admissions was more prominent than NSTEMI. However, the mortality rate was reported higher for NSTEMI admission. Similarly, patients admitted in generalized hospitals were significantly higher than the specialized hospital type, though specialized hospitals showed 9.96% mortality rate higher than the generalized one. The in-hospital mortality rate was 8.6% for our data sample. The mean and standard deviation of LOS was observed significantly associated with patient characteristics including age (for all group), obese (yes/no), insurance (Govt/private), prior myocardial infarction/coronary artery disease (MI/CAD: had/no), history of hypertension (had/no), type of MI (STEMI/NSTEMI) and hospital type (specialized/generalized). [Table 2](#ijerph-16-03890-t002){ref-type="table"} illustrates the detailed statistics of comorbidities associated with in-hospital mortality and length of stay, also presented in [Figure 1](#ijerph-16-03890-f001){ref-type="fig"}. Our findings show that patients with rheumatic heart disease and cerebrovascular disease at time of admission were observed significantly associated with in-hospital mortality. On the other hand, patients conceded with cardiogenic shock, higher level of lipids and thyroid as a comorbid factor were more likely to correlate with an increase in LOS.

3.2. Compliance Measurements {#sec3dot2-ijerph-16-03890}
----------------------------

At a primary level of care,1132 of 1549 patients (73.08%) with AMI furnished with aspirin within three hours of hospital arrival. 785 patients were eligible for receiving beta-blockers, only 306 (38.98%) actually received it. An aggregate of 1634 of 2408 patients (67.86%) was facilitated with clopidogrel. Thrombolytic appeared with the lowest compliance rate of 7.52%. ECG, left ventricular ejection fraction (LVEF) assessment, and coronary angiography were recommended to every chosen patient however just 1664 (62.49%), 1672 (62.79%), and 1767 (66.35%) patients were given the exhorted therapy, individually. Of 2366 patients who were considered as eligible for percutaneous coronary intervention (PCI) treatment, only 884 (37.36%) acquired it. At the secondary dimension of consideration, aspirin appeared with a compliance rate of 47.97%, beta-blocker with 22.29%, clopidogrel with 45.35%, statin with 36.39%, and ACE inhibitor with 38.02%. Among all indicators (at the primary and secondary level of care), the most noteworthy compliance rate was of aspirin whereas, thrombolytic showed the least rate ([Table 3](#ijerph-16-03890-t003){ref-type="table"}).

Aspirin and clopidogrel being pharmacological indicators showed better conformance at hospital level of care whereas in the case of thrombolytic poorer adherence was observed. For PCI, as an invasive procedure, there was no significant conformance observed across hospitals. At secondary level of prevention, hospital adherence was slightly on the rise but yet not satisfactory ([Table 3](#ijerph-16-03890-t003){ref-type="table"}). The median (Interquartile range) composite score for patients was 0.50 (0.38--0.63).

3.3. Association between Process Indicators and Outcomes {#sec3dot3-ijerph-16-03890}
--------------------------------------------------------

[Table 4](#ijerph-16-03890-t004){ref-type="table"} summarizes the results of adjusted and unadjusted regression coefficients with 95% confidence interval for the association between process measures and patient outcome at discharge. 3 out of 8 QIs showed a negative association on in-hospital mortality, although insignificant, which indicates that patients who received aspirin, coronary angiography, and PCI during their hospital stay were at lower risk of dying in the hospital. After adjustment for confounding factors, the results remain unchanged, and no significant differences were observed. In contrast, 4 out of 8 QIs showed strong positive and significant association regarding LOS, which suggested that AMI patients who received clopidogrel, LVEF assessment, coronary angiography, and PCI during their hospital stay were more likely to be associated with an increased LOS. Overall PCI, turned out to be the largest risk factor on account of increased LOS whereas aspirin, beta-blockers and thrombolytic were not considered as predictive indicators.

[Table 5](#ijerph-16-03890-t005){ref-type="table"} summarizes the impact of the patient composite scores on in−hospital mortality. Overall, the patient composite scores were observed insignificantly associated with in−hospital mortality (*p* \> 0.05), although only one measure, i.e., STEMI vs. NSTEMI gives a statistically significant relationship at *p* = 0.05 level. However, at a more aggregate degree, overall composite score (per 10%) was insignificantly but positively associated with in−hospital deaths. The factor with the greatest weight affecting in−hospital mortality is rheumatic heart disease, although found insignificant. On the contrary, the effect of patient composite score on LOS gives a little different result. The effect of patient composite score on LOS for all age groups was found significantly and positively associated at *p* = 0.05 level of significance.

Interestingly, the effect of patient composite score on length of stay for all age groups was found significantly and positively associated at *p* = 0.05 level of significance. Also, STEMI vs. NSTEMI and thyroid patients ended up being statistically significant, with a positive association towards length of stay. More precisely, overall composite score (per10%) was observed statistically significant giving an indication of meaningful addition to our model ([Table 6](#ijerph-16-03890-t006){ref-type="table"}). The median (Interquartile range) composite score for patients was 0.50 (0.38--0.63). As can be seen from these two tables that STEMI vs. NSTEMI is the common factor of patient composite score which is associated with in−hospital mortality and LOS. The overall low quality of patient care was observed based on composite score.

4. Discussion {#sec4-ijerph-16-03890}
=============

This study provides the most recent statistics for evaluating quality of care delivery for patients with acute MI in Pakistan. A well−prepared checklist was administered in order to get the characteristics of AMI patients. Further, this study has observed overall a low compliance rate, which is explicitly lower than the international standards among AMI patients (STEMI and NSTEMI). No significant association was observed between QIs and in−hospital mortality. 4 out of 8 quality indicators showed strong positive and significant association in terms of LOS. Likewise, patient composite score was also observed significantly associated with LOS. Composite performance measures are often attached to regulatory mechanisms whereby hospitals are rewarded or punished according to the outcome of the composite indicator. The use and publication of composite performance measures can generate both positive and negative behavioral responses \[[@B24-ijerph-16-03890]\].

Except for aspirin, other indicators all demonstrated poor compliance rates. This finding is inconsistent with a study from China that reported weak conformance for a few indicators \[[@B25-ijerph-16-03890]\]. The possible reasons for low compliance rate could be the lack of staff and resources at governmental hospitals. Lack of AMI quality improvement programs at hospital levels may be another reason for poor performance in AMI care management. Studies have suggested that AMI patients face significant delays before adequate treatment is available to them. Framework delays and access to reperfusion are distinguished as drivers of destitute compliance rate and remained significant challenges inside the AMI framework of care within the hospitals of Pakistan \[[@B15-ijerph-16-03890],[@B26-ijerph-16-03890]\]. Execution in quality indicators measurement can, subsequently, be progressed by simply expanding adherence to these guidelines. However, the results indicate that serious attention is required to improve the steps of quality of care over 11 hospitals.

Every single indicator must be characterized with the end goal of assessment. Few indicators are time confined, while others such as coronary angiography and PCI are free from time restriction \[[@B11-ijerph-16-03890],[@B27-ijerph-16-03890]\]. Both procedures cost high and most of the eligible patients can't manage the cost of it. In any case, for a clear reason, it is still recommended as procedure of care indicator. The compliance rate should way to deal with 100% when every single qualified patient gets exhorted medication or therapy.

Nonetheless, because occasionally contraindications to advised therapy are not constantly enrolled, the recommended benchmark esteems underneath 100% \[[@B28-ijerph-16-03890]\]. It likewise indicates that there is still opportunity to get better notwithstanding the absence of consistency with guidelines. We found that in univariate analysis the effect of patient's characteristics on LOS is more significant than in−hospital mortality. Also, in multivariate analyses adherence to QIs was found significantly correlated with LOS. Postoperative complications or comorbidities associated at time of admissions may be a reason for increased LOS.

Another finding of this study is the concept of a wide scope of comorbidities associated with the time of admission and their impact on clinical outcomes. The measurement of comorbidities remains an area of concern for scientists and clinicians \[[@B29-ijerph-16-03890]\]. Studies have shown that prolonged hospitalization, decreased quality of life, and increased health−care costs can be affected by comorbidities associated at the time of admissions for patients with AMI \[[@B30-ijerph-16-03890],[@B31-ijerph-16-03890],[@B32-ijerph-16-03890]\]. The main and foremost limitation of our study was inaccessibility of long−term outcome of the selected sampled population. As a result of no subsequent system in Pakistan, it was not in any way conceivable to induce data of these patients after discharge. Therefore, in comparison to others, this study only comprises of patient data during their hospital stay. Another impediment of this study was precision in numerators and denominators.

We believe these results give a credible source of valid information when assessing and improving the quality of medical care. Moreover, this source of information will allow an easier comparison, both within and between countries; this, in turn, leads to more accurate and trustworthy reporting to drive further assessment and improvement in quality of care and outcomes. Clinical indicators function as the spine for assessing the quality of care provided across the full spectrum of domains of patient care \[[@B33-ijerph-16-03890]\]. Therefore, monitoring the health care quality framework, these clinical measures assume an essential job. To ensure their unwavering quality and legitimacy, they should be developed and implemented with transparency.

The therapeutic records of patients in Pakistani hospitals are intended for administrative instead of evaluation purposes, which may have resulted in some evidence being missed or inaccurate. A few patients denied a recommended therapy or left against medical advice on account of their poor budgetary circumstances, so the numerator could be thought little off. Some data about contraindications may be erroneously recorded, causing an overestimation of the denominator. Besides, uncertain affiliations of value measures on healthcare procedures and mortality could likewise be clarified by non−medical care−related variables, e.g., financial status and local healthcare organizations that would influence the health outcomes after discharge. These variables were out of the control of the hospital and will exclusively affect the mortality proportion. Moreover, quality of care measurement depends on the detectability of information gathered in medicinal records and may not precisely reflect care conveyance.

5. Conclusions {#sec5-ijerph-16-03890}
==============

This study in a resource−limited setting, showed some disparities between guidelines and clinical practice. Low adherence to performance measures strongly compel to focus on guideline−based tools for AMI in Pakistan. Taking everything into account, our analyses of the quality of care indicators for AMI patients reveal less satisfactory outcomes. We prescribe a more grounded spotlight on Pakistani national health services regulation and coordination in AMI care and the foundation of national benchmarks for AMI−explicit consideration thrombolytic and PCI related quality indicators to encourage the nature of consideration for AMI patients in Pakistan. Further investigations should be led in other provinces of Pakistan to distinguish, evaluate, and improve the AMI care. Besides, we recommend that clinicians and health care providers use both quality indicators and outcome measures to optimally assess overall clinic quality of care for AMI. The difference in treatment quality between hospitals shows that there is room for improvement in hospitals with poor quality, and it can also help hospitals to make targeted improvements.
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ijerph-16-03890-t001_Table 1

###### 

Univariate relationship between patient characteristics and outcome measures.

  Patient Characteristics    Frequency (%)   In-Hospital Mortality   LOS (day)                   
  -------------------------- --------------- ----------------------- ------------- ------------- ----------
  Age                                                                                            
  \~50                       316 (11.87)     26 (8.23)               0.8170        6.07 ± 3.05   \<0.0001
  50--60                     414 (15.55)     32 (7.73)               7.27 ± 2.50                 
  60--70                     736 (27.64)     61 (8.29)               7.64 ± 2.29                 
  70\~                       1197 (44.95)    109 (9.11)              7.41 ± 2.50                 
  Sex                                                                                            
  Male                       1859 (69.81)    159 (8.55)              0.9803        7.33 ± 2.55   0.6370
  Female                     804 (30.19)     69 (8.58)               7.29 ± 2.59                 
  Obese                                                                                          
  No                         2314 (86.89)    201 (8.69)              0.5544        7.37 ± 2.53   0.0045
  Yes                        349 (13.11)     27 (7.74)               6.96 ± 2.69                 
  Insurance                                                                                      
  Government                 673 (25.27)     60 (8.92)               0.9177        7.16 ± 2.77   0.0040
  Private                    341 (12.81)     28 (8.21)               7.49 ± 2.78                 
  Uninsured                  1649 (61.92)    140 (8.49)              7.70 ± 2.46                 
  Smoking                                                                                        
  No                         1162 (43.63)    95 (8.18)               0.5308        7.32 ± 2.57   0.2555
  Yes                        1501 (56.37)    133 (8.86)              7.31 ± 2.55                 
  Family history of IHD \*                                                                       
  No                         1536 (57.68)    132 (8.59)              0.9451        7.24 ± 2.58   0.1109
  Yes                        1127 (42.32)    96 (8.52)               7.42 ± 2.53                 
  Prior MI/CAD                                                                                   
  No                         1693 (63.57)    153 (9.04)              0.2467        7.23 ± 2.58   0.0214
  Yes                        970 (36.43)     75 (7.73)               7.46 ± 2.58                 
  History Of DM                                                                                  
  No                         1754 (65.87)    151 (8.61)              0.9039        7.26 ± 2.62   0.2349
  Yes                        909 (34.13)     77 (8.47)               7.41 ± 2.42                 
  History of Hypertension                                                                        
  No                         1611 (60.50)    130 (8.07)              0.2612        7.20 ± 2.40   0.0151
  Yes                        1052 (39.50)    98 (9.32)               7.48 ± 2.48                 
  MI                                                                                             
  NSTEMI                     1209 (45.40)    124 (10.26)             0.0044        6.09 ± 2.65   \<0.0001
  STEMI                      1454 (54.60)    104 (7.15)              8.33 ± 1.96                 
  Hospital type                                                                                  
  Specialized                1034 (38.83)    103 (9.96)              0.0397        7.08 ± 2.64   \<0.0001
  Generalized                1629 (61.17)    125 (7.67)              7.46 ± 2.49                 

\* There is 1 missing value. Abbreviation: LOS, length of stay; SD, standard deviation; MI, Myocardial Infarction; IHD, Ischemic Heart Disease; DM, Diabetes Mellitus; CAD, Coronary Artery Disease; STEMI, ST-elevation myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction.

ijerph-16-03890-t002_Table 2

###### 

Univariate analysis of comorbidities with in-hospital mortality and length of stay.

  ------------------------------------------------------------------------------------------------------------
  Comorbidities                 Frequency (%)   In-Hospital Mortality   LOS (day)                   
  ----------------------------- --------------- ----------------------- ------------- ------------- ----------
  Rheumatic\                                                                                        
  heart disease                                                                                     

  no                            2655 (99.70)    226 (8.51)              0.0002        7.32 ± 2.56   0.8367

  yes                           8 (0.30)        2 (25.00)               6.88 ± 3.18                 

  Heart Failure                                                                                     

  no                            2615 (98.20)    222 (8.49)              0.3251        7.31 ± 2.56   0.9827

  yes                           48 (1.80)       6 (12.50)               7.35 ± 2.37                 

  Cardiogenic Shock                                                                                 

  no                            2392 (89.82)    204 (8.53)              0.8550        7.27 ± 2.57   0.0137

  yes                           271 (10.18)     24 (8.86)               7.68 ± 2.43                 

  Hypertension                                                                                      

  no                            1998 (75.03)    167 (8.36)              0.5155        7.30 ± 2.57   0.8212

  yes                           665 (24.97)     61 (9.17)               7.35 ± 2.53                 

  Cerebrovascular disease                                                                           

  no                            2253 (84.60)    205 (9.10)              0.0022        7.29 ± 2.60   0.5060

  yes                           410 (15.40)     23 (5.61)               7.43 ± 2.32                 

  Gastrointestinal disease                                                                          

  no                            2620 (98.39)    226 (8.63)              0.3555        7.32 ± 2.56   0.5060

  yes                           43 (1.61)       2 (4.65)                7.05 ± 2.54                 

  Type-I DM                                                                                         

  no                            2307 (86.63)    200 (8.67)              0.6138        7.29 ± 2.60   0.5357

  yes                           356 (13.37)     28 (7.87)               7.48 ± 2.26                 

  Type-II DM                                                                                        

  no                            2322 (87.19)    197 (8.48)              0.7084        7.33 ± 2.56   0.4519

  yes                           341 (12.81)     31 (9.09)               7.23 ± 2.52                 

  Renal failure                                                                                     

  no                            2451 (92.04)    206 (8.40)              0.3247        7.34 ± 2.54   0.3972

  yes                           212 (7.96)      22 (10.38)              7.00 ± 2.71                 

  Dysrhythmia                                                                                       

  no                            2485 (93.32)    216 (8.69)              0.3689        7.29 ± 2.57   0.1766

  yes                           178 (6.68)      12 (6.74)               7.66 ± 2.69                 

  Peripheral Vascular Disease                                                                       

  no                            2389 (89.71)    201 (8.41)              0.4196        7.30 ± 2.58   0.9493

  yes                           274 (10.29)     27 (9.85)               7.41 ± 2.32                 

  COPD                                                                                              

  no                            2525 (94.82)    215 (8.51)              0.7113        7.30 ± 2.56   0.1561

  yes                           138 (5.18)      13 (9.42)               7.61 ± 2.43                 

  Liver disease                                                                                     

  no                            2615 (98.20)    224 (8.57)              0.9545        7.31 ± 2.56   0.4408

  yes                           48 (1.80)       4 (8.33)                7.60 ± 2.44                 

  Hypercholesterolemia                                                                              

  no                            1614 (60.61)    140 (8.67)              0.7972        7.22 ± 2.59   0.0499

  yes                           1049            88 (8.39)               7.46 ± 2.50                 

  Thyroid Disorder                                                                                  

  no                            1950            175 (8.97)              0.2082        7.19 ± 2.62   \<0.0001

  yes                           713             53 (7.43)               7.65 ± 2.34                 
  ------------------------------------------------------------------------------------------------------------

Abbreviation: LOS, length of stay; SD, standard deviation; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.

ijerph-16-03890-t003_Table 3

###### 

Adherence to performance measures.

  Quality Indicators (QI)                                         Eligible Patients, No. (%) ^a^   Overall Adherence, %   Hospital Variation, Range (%)
  --------------------------------------------------------------- -------------------------------- ---------------------- -------------------------------
  QI1: Aspirin prescribed within 3h of hospital arrival           1549 (58.17)                     73.08                  62.11--85.81
  QI2: Beta-blockers within 12h of arrival                        785 (23.69)                      38.98                  32.89--45.45
  QI3: Clopidogrel within 12h of arrival                          2408 (90.42)                     67.86                  62.68--73.27
  QI4: Thrombolytics received within 30 min of hospital arrival   971 (36.46)                      7.52                   3.57--11.43
  QI5: ECG within 10 min of hospital arrival                      2663 (100.00)                    62.49                  57.74--71.84
  QI6: Left ventricular function assessment                       2663 (100.00)                    62.79                  56.33--67.53
  QI7: Coronary angiography performed during hospital stay        2663 (100.00)                    66.35                  60.85--71.78
  QI8: Primary PCI                                                2366 (88.85)                     37.36                  29.52--43.59
  Prescription filled post-discharge                                                                                      
  QI9: Aspirin                                                    1549 (58.17)                     47.97                  38.51--61.29
  QI10: Beta-blocker                                              785 (29.48)                      22.29                  10.94--34.21
  QI11: Clopidogrel                                               2408 (90.42)                     45.35                  35.36--53.59
  QI12: Statin                                                    2020 (75.85)                     36.39                  30.11--41.76
  QI13: ACE inhibitor                                             2567 (96.40)                     38.02                  29.70--45.54
  Outcome indicators                                                                                                      
  In-hospital mortality                                           2663 (100.00)                    8.56                   5.56--12.50

Abbreviation: PCI, percutaneous coronary intervention. ^a^ Eligible patients are those with definite indications but no documented contraindications.
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###### 

Association of process measures with clinical outcomes among acute myocardial infarction patients.

  Quality Indicators^\*^   In−Hospital Mortality   Length of Stay                         
  ------------------------ ----------------------- ------------------ ------------------- -------------------
  QI1                      −0.0258 (0.9014)        −0.0382 (0.8540)   0.1668 (0.1880)     0.2930 (0.0340)
  QI2                      0.1174 (0.6616)         0.1079 (0.6856)    0.1873 (0.2207)     0.2337 (0.1456)
  QI3                      0.0238 (0.8831)         0.0156 (0.9229)    0.5278 (\<0.0001)   0.7994 (\<0.0001)
  QI4                      0.5451 (0.1898)         0.6093 (0.1457)    −0.4913 (0.0351)    −0.4994 (0.0328)
  QI5                      0.0342 (0.8177)         0.0525 (0.7229)    −0.2179 (0.0159)    −0.2913 (0.0043)
  QI6                      0.0048 (0.9742)         −0.0636 (0.6647)   0.4251 (\<0.0001)   0.8413 (\<0.0001)
  QI7                      −0.0786 (0.6057)        −0.1535 (0.3110)   0.9974 (\<0.0001)   1.5171 (\<0.0001)
  QI8                      −0.1276 (0.4603)        −0.2174 (0.2102)   1.2699 (\<0.0001)   1.7515 (\<0.0001)

\* The definition of quality indicators (QIs) please refer to [Table 3](#ijerph-16-03890-t003){ref-type="table"}. All significant (*p* \< 0.10) risks factors (listed in [Table 1](#ijerph-16-03890-t001){ref-type="table"}) in univariate analysis for patient characters were included in the hierarchical generalized linear model.
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###### 

Effect of patient composite scores on in−hospital mortality.

  Factors                                Regression Coefficient, 95%CI   *p* Value
  -------------------------------------- ------------------------------- -----------
  STEMI vs. NSTEMI                       1.451 (1.026, 2.053)            0.0379
  Generalized vs. Specialized Hospital   0.877 (0.613, 1.254)            0.4270
  Cerebra disease                        0.620 (0.355, 1.082)            0.0849
  Rheumatic Heart Disease (RHD)          2.346 (0.070, 78.121)           0.4952
  Composite score (per 10%)              1.003 (0.937, 1.073)            0.9284

The composite score was added as a continuous predictor variable, and regression coefficients were reported per 10% increment in composite score. Abbreviation: STEMI, ST-elevation myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction.
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###### 

Effect of patient composite scores on length of stay.

  Factors                                Regression Coefficient, 95%CI   *p* Value
  -------------------------------------- ------------------------------- -----------
  Age                                                                    
  50--60 vs. \~50                        0.481 (0.132, 0.829)            0.0069
  60--70 vs. \~50                        0.751 (0.432, 1.071)            \<0.0001
  70\~ vs. \~50                          0.587 (0.282, 0.891)            0.0002
  Insurance                                                              
  Government vs. Uninsured               0.147 (−0.059, 0.354)           0.1623
  Private vs. Uninsured                  0.202 (−0.069, 0.474)           0.1443
  Prior MI/CAD                           0.021 (−0.210, 0.251)           0.8595
  History of Hypertension                0.137 (−0.091, 0.365)           0.2401
  STEMI vs. NSTEMI                       2.049 (1.871, 2.227)            \<0.0001
  Generalized vs. Specialized hospital   0.168 (−0.164, 0.499)           0.3213
  thyroid                                0.257 (0.058, 0.455)            0.011
  lipids                                 0.179 (−0.001, 0.359)           0.051
  Composite score (per 10%)              0.258 (0.217, 0.299)            \<0.0001

The composite score was added as a continuous predictor variable, and regression coefficients were reported per 10% increment in composite score. Abbreviation: MI, Myocardial Infarction; CAD, Coronary Artery Disease; STEMI, ST-elevation myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction.
